Evaluation of systemic Rituximab for treating orbital MALT lymphoma

Evaluation of systemic Rituximab for treating orbital MALT lymphoma - Evaluation of systemic Rituximab for treating orbital MALT lymphoma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009512

Enrollment

Registered

2012-12-11

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orbital MALT lymphoma

Interventions

Systemic injection of Rituximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients had a history for biopy-proven orbital MALT lymphoma with or without prior systemic anti-cancer treatment.

Exclusion criteria

Exclusion criteria: The patients who have history of myocardial infarction and brain infarction.

Design outcomes

Primary

Measure	Time frame
best-corrected visual acuity, intraocular pressure, indirect ophthalmoscopy, and slit-lamp examination before and after every treatment	—

Countries

Japan

Contacts

Public ContactNoriyasu Hashida

Osaka University Graduate School of Medicine Department of Ophthalmology

nhashida@ophthal.med.osaka-u.ac.jp06-6879-3456

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026